CD8A and neoplasm: The combination of trametinib with anti-PD-1 increased tumor-infiltrating CD8+ T cells in CT26 mouse colon carcinoma tumors, as well as downregulating immunosuppressive factors, upregulating HLA molecules, and increasing immune responses in the tumors yes [104].